Document:

exh10-17.htm

 

Exhibit 10.17

 Cooperation Agreement

Party A: Hangzhou Pengtuo Animation Technology Co. Ltd.

Party B: Hangzhou Kunjiang Education Technology Co. Ltd.

Through friendly consultations, Party A and Party B enter into the following agreement regarding jointly developing a 3D Cartoon names “Colony” (“Colony”).

I.  Contents on cooperation

The cartoon “Colony”

II. Party A and Party B’s mutual responsibilities

	
  

	
1)

	
Party A shall be responsible for the complete process, such as preliminary planning, animation, post processing and animation synthesis etc.

	
  

	
2)

	
Party B shall be responsible for marketing and promotion.

III. Capital Investment

The total investment is RMB 1.4 million. Among this amount, Party A shall invest RMB 450,000 and Party B shall invest RMB 950,000. The investment from both parties with one time payment shall be in place before November 25, 2010.

	
  

	
IV. Term of the Cooperation

From November 15, 2010 to November 15, 2015.

	
  

	
V. Profit Distribution

            The list of source of revenue:

	
  

	
1)

	
The production of PC Console Games, online Games, PS2, Will, NDSL, PSP, mobile games etc.

	
  

	
2)

	
The operation of Card Trading Game Systems.

	
  

	
3)

	
Garage kit,plush toys, cell phone accessories and related products.

	
  

	
4)

	
Distribution on the oversea copyright of the cartoon  through various channels

	
  

	
5)

	
Copyright sales through book publishers.

	
  

	
6)

	
Copyright revenue from image usage of the Cartoon characters.

  

  

  

	
  

	
7)

	
Publish special edition such as drawing comic stories, seeing recreated works etc.

	
  

	
8)

	
Copyright revenue from audio/video products sales through audio and video products publisher and Audio-visual products vendors.

	
  

	
9)

	
Broadcasting revenue from TV stations and related advertisement revenue.

	
  

	
10)

	
Revenue from trademark sales and copyright of the cartoon design.

	
  

	
11)

	
Online sales revenue from virtual commodities.

	
  

	
12)

	
Franchised chain stores and amusement part.

This project will be managed with independent accounting. Profit distribution: Party A account for 30%, and Party B account for 70%. VI. For outstanding issues, Party A and Party B shall settle through negotiation. VII This Agreement contains two original copies and each party has one copy.

Party A: Hangzhou Pengtuo Animation Technology Co. Ltd.

(Seal)

Representative Signature: (Signed)

Party B: Hangzhou Kunjiang Education Technology Co. Ltd.

(Seal)

Representative Signature: (Signed)

Date: Nov. 15, 2010ex10-1iv.htm

EXHIBIT 10.1(iv)

 

AMENDMENT

This Amendment is made as of this 24th day of January 2011, by and between YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”); and

BIOCANCELL THERAPEUTICS ISRAEL LTD. of Beit Beck, Har Hotzvim, Jerusalem, Israel (the “Company"), of the second part;

WHEREAS, the Company and Yissum executed an amended and restated license agreement on November 14, 2005, as supplemented and amended (the “License Agreement”), pursuant to which the Company obtained an exclusive license to certain patents owned by Yissum; and

WHEREAS the Parties wish to amend the License Agreement to add new patents and patent applications to the list of Patents exclusively licensed to the Company as part of the Licensed Technology.

 

 

NOW THEREFORE, in consideration of the mutual promises and covenants set forth herein, the parties hereby agree, as follows:

	
1.

	
All capitalized terms not defined herein shall have the meaning ascribed to them in the License Agreement.

	
2.

	
Appendix 1 of the License Agreement shall be amended to add the following patents and patent applications:

	
  

	
·

	
NUCLEIC ACID CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME FOR TREATING CANCER (H19 + Tnf Alpha), Yissum Ref# 2989

	
  

	
·

	
NUCLEIC ACID AGENTS FOR DOWNREGULATING H19, AND METHODS OF USING SAME, Yissum Ref# 3025

	
  

	
·

	
NUCLEIC ACID CONSTRUCTS AND METHODS FOR SPECIFIC SILENCING OF H19   (siRNA H19 - cancer + stem cells) Yissum Ref# 3309

	
  

	
·

	
H19 SILENCING NUCLEIC ACID AGENTS FOR TREATING RHEUMATOID ARTHRITIS   (siRNA - RA), Yissum Ref# 3310

	
  

	
·

	
CONSTRUCTS CONTAINING MULTIPLE EXPRESSION CASSETTES FOR CANCER THERAPY, Yissum Ref# 3423

A new Appendix 1 to the License Agreement, including Yissum Reference Numbers, is annexed to this Amendment.

	
3.

	
All other provisions of the License Agreement, including, without limitation, all terms of the Amendment to License Agreement dated September 11, 2007 which shall apply to the terms hereof,  shall continue to have the same force and effect as they had prior to this Addendum.

IN WITNESS WHEREOF, the parties have executed this Agreement as a deed and delivered on the date first above written.

                                                                                                                                                         

	
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD

 

	  	
BIOCANCELL THERAPEUTICS ISRAEL, LTD.

	
By: /s/ Shoshi Keynan

Shoshi Keynan

	
/s/ Yaakov Michlin

Yaakov Michlin

	  	
By: /s/ Uri Danon

Uri Danon

	
 /s/ Ira Weinstein

Ira Weinstein

	
Title: VP Licensing, Pharmaceuticals

	 President & CEO	  	
Title: CEO

	 CFO
	
Date: 30/1/2011

	  30/1/2011	  	
Date: 24/1/11

	  24/1/11

  

  

  

APPENDIX 1 – THE PATENTS

	
Family:

	
2148

	
Title:

	
Sensitive Cancer Assay

	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Inventor

	
Faculty/Department

	  	  	  	  	  	  	  
	
Ariel Ilana

	
Hadassah

	  	  	  	  	  	  	  
	
Hochberg Avraham

	
HUJI Faculty of Science The Alexander Silberman Institute for Life Sciences

	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	
Application

	
Publication

	
Patent

	
Patent ID

	
Status

	
Country

	
Date

	
Number

	
Date

	
Number

	
Date

	
Number

	
2148-00

	
Granted

	
Israel

	
7/3/1994

	
108879

	  	  	
31/08/2000

	
108879

	
2148-01

	
Published

	
PCT

	
6/3/1995

	
PCT/EP95/00823

	
4/9/1995

	
WO95/24503

	  	  
	
2148-03

	
Granted

	
US

	
6/9/1996

	
08/704,786

	  	  	
21/09/1999

	
5,955,273

	
2148-04

	
Granted

	
Europe

	
6/3/1995

	
95927570

	  	  	
29/05/2002

	
759092

	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Family:

	
2324

	
Title:

	
Methods and Compositions for Inducing Tumor-Specific Cytotoxicity

	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Inventor

	
Faculty/Department

	  	  	  	  	  	  	  
	
Ayesh Suhail

	
HUJI Faculty of Science The Alexander Silberman Institute for Life Sciences

	  	  	  	  	  	  	  
	
Hochberg Avraham

	
HUJI Faculty of Science The Alexander Silberman Institute for Life Sciences

	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  

 

 

  

  

  

 

	  	  	  	  	  	  	  	  	  
	  	
Application

	
Publication

	
Patent

	
Patent ID

	
Status

	
Country

	
Date

	
Number

	
Date

	
Number

	
Date

	
Number

	
2324-00

	
Abandoned

	
US

	
3/10/1997

	
08/943,608

	  	  	  	  
	
2324-01

	
Exhausted

	
PCT

	
4/10/1998

	
PCT/IL98/00486

	
8/12/1999

	
WO 99/18195

	  	  
	
2324-02

	
Exhausted

	
PCT

	
22/10/2002

	
PCT/IL02/00843

	
1/5/2003

	
WO 03/035883

	  	  
	
2324-03

	
Granted

	
US

	
1/10/1998

	
09/165,240

	  	  	
11/7/2000

	
6,087,164

	
2324-04

	
Granted

	
China

	
4/10/1998

	
98811834

	  	  	
30/11/2005

	
ZL 98811833.5

	
2324-05

	
Granted

	
Europe

	
4/10/1998

	
98947759

	  	
1019499

	
10/9/2008

	
1019499

	
2324-06

	
Filed

	
Hungary

	
4/10/1998

	
P0003745

	  	  	  	  
	
2324-07

	
Granted

	
Israel

	
4/10/1998

	
135430

	
19/08/2007

	
Pat & Designs J. 6/2007

	
20/11/2007

	
135430

	
2324-08

	
Granted

	
Korea

	
4/10/1998

	
2000-7003609

	  	  	
20/10/2005

	
524262

	
2324-09

	
Filed

	
Mexico

	
4/10/1998

	
2000-003843

	  	  	  	  
	
2324-10

	
Abandoned

	
New Zealand

	
4/10/1998

	
503843

	  	  	  	  
	
2324-11

	
Allowed

	
Norway

	
4/10/1998

	
20001684

	  	  	  	  
	
2324-12

	
Abandoned

	
Poland

	
4/10/1998

	
P339949

	  	  	  	  
	
2324-13

	
Granted

	
Russian Federation

	
4/10/1998

	
2E+09

	  	
2214280

	
20/10/2003

	
2214280

	
2324-14

	
Granted

	
US

	
10/5/2000

	
09/568,059

	  	  	
23/10/2001

	
6,306,833

	
2324-15

	
Granted

	
US

	
22/10/2001

	
10/012,131

	
29/04/2004

	
US-2004-0082529

	
9/5/2006

	
7,041,654

	
2324-16

	
Granted

	
Australia

	
4/10/1998

	
94571/98

	  	  	
19/12/2002

	
755774

	
2324-17

	
Examination

	
Japan

	
4/10/1998

	
2000-514993

	  	  	  	  
	
2324-18

	
Granted

	
Canada

	
4/10/1998

	
2,308,124

	  	  	
8/7/2008

	
2,308,124

	
2324-19

	
Granted

	
Singapore

	
4/10/1998

	
200001824-2

	  	  	
4/6/2002

	
72207

	
2324-20

	
Granted

	
Czech Republic

	
4/10/1998

	
PV2000-1201

	  	  	
16/02/2005

	
294694

	
2324-21

	
Abandoned

	
Europe

	
22/10/2002

	
2779859.4

	
21/07/2004

	
1438412

	  	  
	
2324-22

	
Abandoned

	
China

	
22/10/2002

	
2825940.8

	  	  	  	  
	
2324-23

	
Abandoned

	
Japan

	
22/10/2002

	
2003-538383

	  	  	  	  
	
2324-24

	
Abandoned

	
Israel

	
22/10/2002

	
161553

	  	  	  	  
	
2324-25

	
Abandoned

	
Canada

	
22/10/2002

	
2,464,394

	  	  	  	  
	
2324-26

	
Abandoned

	
Australia

	
22/10/2002

	
2.002E+09

	  	  	  	  
	
2324-27

	
Abandoned

	
Mexico

	
22/10/2002

	
PAa2004/003732

	  	  	  	  
	
2324-28

	
Granted

	
Czech Republic

	
18/06/2004

	
PV 2004-741

	  	  	
14/02/2005

	
294941

	
2324-29

	
Allowed

	
Brazil

	
4/10/1998

	
PI9812717-9

	  	  	  	  
	
2324-30

	
Examination

	
Japan

	
24/05/2006

	
2006-144648

	
9/11/2006

	
2006-304801

	  	  
	
2324-31

	
Granted

	
Mexico

	
4/10/1998

	
PA/a/2000/03251

	  	  	
10/4/2007

	
244867

	
2324-32

	
Examination

	
Japan

	
24/05/2006

	
2007-270777

	
19/06/2008

	
2008-136480

	  	  
	
2324-33

	
Filed

	
Norway

	  	
20093194

	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  

 

 

  

  

  

 

	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  
	
Family:

	
2989

	
Title:

	
Nucleic Acid Constructs, Pharmaceutical Compositions and Methods of Using Same for Treating Cancer (H19 + Tnf Alpha)

	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Inventor

	
Faculty/Department

	  	  	  	  	  	  	  
	
Hochberg Avraham

	
HUJI Faculty of Science The Alexander Silberman Institute for Life Sciences

	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	
Application

	
Publication

	
Patent

	
Patent ID

	
Status

	
Country

	
Date

	
Number

	
Date

	
Number

	
Date

	
Number

	
2989-00

	
Expired

	
US

	
22/09/2005

	
60/719,178

	  	  	  	  
	
2989-01

	
Exhausted

	
PCT

	
21/09/2006

	
PCT/IL2006/001110

	
29/03/2007

	
WO 2007/034487

	  	  
	
2989-02

	
Examination

	
US

	
21/09/2006

	
12/067,410

	  	  	  	  
	
2989-03

	
Examination

	
Israel

	
21/09/2006

	
190311

	  	  	  	  
	
2989-04

	
Published

	
Japan

	
21/09/2006

	
2008-531883

	
5/3/2009

	
2009-508516

	  	  
	
2989-05

	
Granted

	
Europe

	
21/09/2006

	
6780498.9

	
4/6/2008

	
1926814

	
28/04/2010

	
1926814

	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Family:

	
3025

	
Title:

	
NUCLEIC ACID AGENTS FOR DOWNREGULATING H19, AND METHODS OF USING SAME

	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Inventor

	
Faculty/Department

	  	  	  	  	  	  	  
	
Matouk Imad

	
HUJI Faculty of Science The Alexander Silberman Institute for Life Sciences

	  	  	  	  	  	  	  
	
Hochberg Avraham

	
HUJI Faculty of Science The Alexander Silberman Institute for Life Sciences

	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	
Application

	
Publication

	
Patent

	
Patent ID

	
Status

	
Country

	
Date

	
Number

	
Date

	
Number

	
Date

	
Number

	
3025-00

	
Expired

	
US

	
7/7/2005

	
60/696,795

	  	  	  	  
	
3025-01

	
Exhausted

	
PCT

	
6/7/2006

	
PCT/IL2006/000785

	
18/01/2007

	
WO 2007/007317

	  	  
	
3025-02

	
Examination

	
US

	
16/01/2008

	
12/015,325

	  	  	  	  
	
3025-03

	
Published

	
Japan

	
6/7/2006

	
2008-520061

	
11/12/2008

	
2008-545011

	  	  
	
3025-04

	
Examination

	
US

	
6/7/2006

	
11/994,810

	
4/6/2009

	
US- 2009/0143321 A1

	  	  
	
3025-05

	
Filed

	
Canada

	
6/7/2006

	
2,614,531

	  	  	  	  
	
3025-06

	
Exhausted

	
Australia

	
6/7/2006

	
2.006E+09

	  	  	  	  
	
3025-07

	
Examination

	
Europe

	
6/7/2006

	
6766118.1

	
30/04/2008

	
1915448

	  	  
	
3025-08

	
Filed

	
India

	
6/7/2006

	
2008/DELNP/758

	  	  	  	  
	
3025-09

	
Examination

	
China

	
21/05/2006

	
2.007E+11

	  	  	  	  
	
3025-10

	
Examination

	
Israel

	  	
188501

	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Family:

	
3309

	
Title:

	
NUCLEIC ACID CONSTRUCTS AND METHODS FOR SPECIFIC SILENCING OF H19 (siRNA H19 - cancer + stem cells)

	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Inventor

	
Faculty/Department

	  	  	  	  	  	  	  
	
Hochberg Avraham

	
HUJI Faculty of Science The Alexander Silberman Institute for Life Sciences

	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	
Application

	
Publication

	
Patent

	
Patent ID

	
Status

	
Country

	
Date

	
Number

	
Date

	
Number

	
Date

	
Number

	
3309-00

	
Expired

	
US

	
16/01/2007

	
60/880,425

	  	  	  	  
	
3309-01

	
Exhausted

	
PCT

	
16/01/2008

	
PCT/IL2008/000072

	
24/07/2008

	
WO 2008/087642 A2

	  	  
	
3309-02

	
Examination

	
Europe

	
16/01/2008

	
8702653

	
28/10/2009

	
2111450

	  	  
	
3309-03

	
Filed

	
Israel

	
16/01/2008

	
199867

	  	  	  	  
	
3309-04

	
Filed

	
Canada

	
16/01/2008

	
2,675,967

	  	  	  	  
	
3309-05

	
Published

	
US

	
16/01/2008

	
12/523,298

	
8/4/2010

	
US-2010/0086526 A1.

	  	  
	
3309-06

	
Filed

	
India

	
16/01/2008

	
5257/DELNP/2009

	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Family:

	
3310

	
Title:

	
H19 SILENCING NUCLEIC ACID AGENTS FOR TREATING RHEUMATOID ARTHRITIS (siRNA - RA)

	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Inventor

	
Faculty/Department

	  	  	  	  	  	  	  
	
Hochberg Avraham

	
HUJI Faculty of Science The Alexander Silberman Institute for Life Sciences

	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	
Application

	
Publication

	
Patent

	
Patent ID

	
Status

	
Country

	
Date

	
Number

	
Date

	
Number

	
Date

	
Number

	
3310-00

	
Expired

	
US

	
16/01/2007

	
60/880,430

	  	  	  	  
	
3310-01

	
Exhausted

	
PCT

	
16/01/2008

	
PCT/IL2008/000071

	
24/07/2008

	
WO 2008/087641 A2

	  	  
	
3310-02

	
Examination

	
Europe

	
16/01/2008

	
8702652

	
28/10/2009

	
2111449

	  	  
	
3310-03

	
Filed

	
Canada

	
16/01/2008

	
2,675,964

	  	  	  	  
	
3310-04

	
Allowed

	
US

	
16/01/2008

	
12/523,288

	
29/04/2010

	
US- 2010/0105759 A1

	  	  
	
3310-05

	
Filed

	
Israel

	
16/01/2008

	
199866

	  	  	  	  
	
3310-06

	
Filed

	
India

	
16/01/2008

	
5271/DELNP/2009

	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Family:

	
3423

	
Title:

	
CONSTRUCTS CONTAINING MULTIPLE EXPRESSION CASSETTES FOR CANCER THERAPY

	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
Inventor

	
Faculty/Department

	  	  	  	  	  	  	  
	
Amit Doron

	
 HUJI Faculty of Science The Alexander Silberman Institute for Life Sciences

	  	  	  	  	  	  	  
	
Hochberg Avraham

	
HUJI Faculty of Science The Alexander Silberman Institute for Life Sciences

	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	
Application

	
Publication

	
Patent

	
Patent ID

	
Status

	
Country

	
Date

	
Number

	
Date

	
Number

	
Date

	
Number

	
3423-00

	
Expired

	
US

	
25/10/2007

	
60/982,442

	  	  	  	  
	
3423-01

	
Exhausted

	
PCT

	
23/10/2008

	
PCT/IL2008/001405

	
30/04/2009

	
WO 2009/053982

	  	  
	
3423-02

	
Filed

	
Russian Federation

	
23/10/2008

	
2.01E+09

	  	  	  	  
	
3423-03

	
Published

	
US

	
23/10/2010

	
12/738,620

	
7/10/2010

	
US 2010/0256225 A1

	  	  
	
3423-04

	
Filed

	
Canada

	
23/10/2008

	
2,703,774

	  	  	  	  
	
3423-05

	
Filed

	
Brazil

	
23/10/2008

	
PI 0818937-4

	  	  	  	  
	
3423-06

	
Filed

	
India

	
23/10/2008

	
2846/DELNP/2010

	  	  	  	  
	
3423-07

	
Pre-Filing

	
Korea

	  	  	  	  	  	  
	
3423-08

	
Filed

	
China

	
23/10/2008

	
2.009E+11

	  	  	  	  
	
3423-09

	
Examination

	
Europe

	
23/10/2008

	
8842129.2

	
7/7/2010

	
2203187

	  	  
	
3423-10

	
Filed

	
Israel

	
23/10/2008

	
205048

	  	  	  	  
	
3423-11

	
Filed

	
Australia

	
23/10/2008

	
2.008E+09

	  	  	  	  
	
3423-12

	
Filed

	
Japan

	
23/10/2008

	
2010-530628

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}]]